WO2023241738A3 - Composé de 1,4-benzodiazépine et utilisation associée dans la préparation d'un médicament antitumoral - Google Patents
Composé de 1,4-benzodiazépine et utilisation associée dans la préparation d'un médicament antitumoral Download PDFInfo
- Publication number
- WO2023241738A3 WO2023241738A3 PCT/CN2023/112421 CN2023112421W WO2023241738A3 WO 2023241738 A3 WO2023241738 A3 WO 2023241738A3 CN 2023112421 W CN2023112421 W CN 2023112421W WO 2023241738 A3 WO2023241738 A3 WO 2023241738A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- preparation
- compound
- benzodiazepine compound
- tumors
- Prior art date
Links
- -1 1,4-benzodiazepine compound Chemical class 0.000 title abstract 5
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 229940041181 antineoplastic drug Drugs 0.000 title abstract 2
- 102000004120 Annexin A3 Human genes 0.000 abstract 4
- 108090000670 Annexin A3 Proteins 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 201000002313 intestinal cancer Diseases 0.000 abstract 1
- 230000009545 invasion Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000017854 proteolysis Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C07D243/28—Preparation including building-up the benzodiazepine skeleton from compounds containing no hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention appartient au domaine technique de la chimie pharmaceutique et des médicaments, se rapportant à un composé de 1,4-benzodiazépine et une utilisation associée dans la préparation d'un médicament antitumoral, en particulier, une utilisation du composé de 1,4-benzodiazépine dans la préparation d'un agent de dégradation de l'annexine A3 (ANXA3) et une utilisation du composé de 1,4-benzodiazépine dans la préparation d'un médicament pour le traitement de cancers. En particulier, l'invention concerne une utilisation du composé de 1,4-benzodiazépine, ou d'un sel pharmaceutiquement acceptable ou d'un stéréoisomère associé, ou d'une composition pharmaceutique utilisant le composé en tant que principe actif dans la préparation d'un médicament pour la prévention et le traitement de tumeurs. Le composé peut se lier à la protéine ANXA3, induire une dégradation de la protéine ANXA3, inhiber la prolifération, le clonage, la migration, l'invasion et d'autres fonctions des cellules tumorales, et exercer un effet de traitement antitumoral in vivo. La méthode peut être utilisée pour traiter des tumeurs solides, des tumeurs sanguines et d'autres maladies, et les tumeurs impliquées comprennent le cancer du sein, le cancer du col de l'utérus, le cancer de l'ovaire, le cancer de l'intestin, le cancer de l 'estomac, le cancer du pancréas, le cancer du poumon, le cancer de l'œsophage, le cancer du foie, la leucémie et le mélanome.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210680501.3 | 2022-06-15 | ||
| CN202210680501.3A CN117263873A (zh) | 2022-06-15 | 2022-06-15 | 1,4-苯二氮䓬类化合物及其在制备抗肿瘤药物中的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023241738A2 WO2023241738A2 (fr) | 2023-12-21 |
| WO2023241738A3 true WO2023241738A3 (fr) | 2024-02-15 |
Family
ID=89192363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2023/112421 WO2023241738A2 (fr) | 2022-06-15 | 2023-08-11 | Composé de 1,4-benzodiazépine et utilisation associée dans la préparation d'un médicament antitumoral |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN117263873A (fr) |
| WO (1) | WO2023241738A2 (fr) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999067221A1 (fr) * | 1998-06-22 | 1999-12-29 | Elan Pharmaceuticals, Inc. | COMPOSES D'INHIBITION DE LA LIBERATION DU PEPTIDE β-AMYLOIDE ET/OU DE SA SYNTHESE |
| WO2000066106A2 (fr) * | 1999-04-30 | 2000-11-09 | The Regents Of The University Of Michigan | Applications therapeutiques de benzodiazepines pro-apoptotiques |
| WO2003051274A2 (fr) * | 2001-12-14 | 2003-06-26 | Astrazeneca Ab | Derives de la benzodiazepine, leur preparation et leur utilisation |
| CN1596114A (zh) * | 2001-11-13 | 2005-03-16 | 三维药物公司 | 取代的1,4－苯并二氮杂䓬类及其在治疗癌症中的应用 |
| CN104822677A (zh) * | 2012-09-21 | 2015-08-05 | 百时美施贵宝公司 | 氟烷基-1,4-苯并二氮杂*酮化合物 |
-
2022
- 2022-06-15 CN CN202210680501.3A patent/CN117263873A/zh active Pending
-
2023
- 2023-08-11 WO PCT/CN2023/112421 patent/WO2023241738A2/fr unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999067221A1 (fr) * | 1998-06-22 | 1999-12-29 | Elan Pharmaceuticals, Inc. | COMPOSES D'INHIBITION DE LA LIBERATION DU PEPTIDE β-AMYLOIDE ET/OU DE SA SYNTHESE |
| WO2000066106A2 (fr) * | 1999-04-30 | 2000-11-09 | The Regents Of The University Of Michigan | Applications therapeutiques de benzodiazepines pro-apoptotiques |
| CN1596114A (zh) * | 2001-11-13 | 2005-03-16 | 三维药物公司 | 取代的1,4－苯并二氮杂䓬类及其在治疗癌症中的应用 |
| WO2003051274A2 (fr) * | 2001-12-14 | 2003-06-26 | Astrazeneca Ab | Derives de la benzodiazepine, leur preparation et leur utilisation |
| CN104822677A (zh) * | 2012-09-21 | 2015-08-05 | 百时美施贵宝公司 | 氟烷基-1,4-苯并二氮杂*酮化合物 |
Non-Patent Citations (2)
| Title |
|---|
| HAUGHIAN JAMES M., PINTO MAURICIO P., HARRELL J. CHUCK, BLIESNER BRIAN S., JOENSUU KRISTIINA M., DYE WENDY W., SARTORIUS CAROL A.,: "Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 8, 21 February 2012 (2012-02-21), pages 2742 - 2747, XP093140336, ISSN: 0027-8424, DOI: 10.1073/pnas.1106509108 * |
| LIANG YONGXI, MIN DELIN, FAN HULIN, LIU KUNLIN, TU JUCHUANLI, HE XUEYAN, LIU BINGJIE, ZHOU LU, LIU SULING, SUN XUN: "Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer", ACTA PHARMACEUTICA SINICA B, vol. 13, no. 4, 1 April 2023 (2023-04-01), pages 1686 - 1698, XP093140337, ISSN: 2211-3835, DOI: 10.1016/j.apsb.2022.11.023 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117263873A (zh) | 2023-12-22 |
| WO2023241738A2 (fr) | 2023-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lissoni | Is there a role for melatonin in supportive care? | |
| EP3311841B1 (fr) | Agent anticancéreux | |
| HUP0303976A2 (hu) | Kombinációs terápia anti-EGFR-ellenanyagok és hormonantagonisták együttes alkalmazásával | |
| EP3034076B1 (fr) | Utilisation combinée d'un médicament anti-cancéreux et d'un composé de la classe des isothiocyanates | |
| JP2002537333A (ja) | 相乗作用性抗腫瘍組成物 | |
| EP3042669B1 (fr) | Agent antitumoral et promoteur de l'effet antitumoral | |
| KR20190077449A (ko) | 암 및 암 합병증의 치료학적 처치에 사용하기 위한 약제학적 조성물 | |
| MX2022012351A (es) | Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres. | |
| KR20090069279A (ko) | 엔도셀린 효능제 투여를 통한 방사선 요법에 대한 종양 세포의 감작 | |
| EP2732044B1 (fr) | Nouvelles compositions de peptides en doigts de zinc utilisées comme agents puissants pour la prévention et le traitement du cancer | |
| WO2023241738A3 (fr) | Composé de 1,4-benzodiazépine et utilisation associée dans la préparation d'un médicament antitumoral | |
| KR20090034355A (ko) | 암 치료에 기여하는 방법, 조성물 및 제조품 | |
| MX2024003563A (es) | Composicion farmaceutica combinada de inhibidor de cdk4/6 e inhibidor de aromatasa. | |
| KR102694803B1 (ko) | A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용 | |
| MX2023009962A (es) | Composicion farmaceutica combinada que contiene inhibidor de cdk4/6 y su uso. | |
| WO2022174064A3 (fr) | Composition thérapeutique et procédé combinant une immunothérapie multiplex avec un vaccin contre le cancer pour le traitement du cancer | |
| AU2004296129A1 (en) | CHP-gemcitabin combined agent and use thereof as anti-tumoural active substances | |
| WO2024073328A3 (fr) | Procédés de traitement du cancer et compositions associées | |
| Białczyk et al. | Abscopal effect in solid tumors. Potential mechanisms, application of radioimmunotherapy, and a review of exemplary clinical cases | |
| JP2002537334A (ja) | 相乗作用性抗腫瘍組成物 | |
| CN100338041C (zh) | 明胶酶抑制剂与抗肿瘤剂的组合以及其应用 | |
| Eckhardt | Phase I and II studies with hexitol derivatives, formyl-leurosine and ftorafur | |
| RU2023127510A (ru) | Экзосомы, нагруженные fas-ассоциированным фактором 1 (faf1), и их применение в качестве противоопухолевого средства | |
| AU2008240300B2 (en) | Methods and compositions for contributing to the treatment of cancers | |
| JP2022551672A (ja) | 乳癌治療法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23823304 Country of ref document: EP Kind code of ref document: A2 |